PT-141

PT-141 is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that activates melanocortin receptors — specifically MC1R, MC3R, and MC4R — in the central nervous system. Its mechanism is fundamentally different from sexual function drugs like sildenafil (Viagra) or tadalafil (Cialis), which work by increasing blood flow to genital tissue. PT-141 works upstream, acting on brain circuits involved in sexual arousal and desire. The compound was originally developed from Melanotan II — a peptide studied for tanning — when researchers noticed that sexual arousal was a pronounced side effect in clinical trials. PT-141 was refined from that observation to selectively target sexual function while minimizing some of Melanotan II's other effects. FDA approved in 2019 under the brand name Vyleesi (marketed by AMAG Pharmaceuticals), PT-141 is indicated for premenopausal women with acquired, generalized HSDD. Off-label use in men — for whom it has shown efficacy in improving erectile function and libido in studies — is widespread in both prescription and research chemical contexts.

Sexual desire enhancement is PT-141's core mechanism-validated benefit. By activating melanocortin receptors in hypothalamic and limbic brain regions involved in sexual motivation, it produces genuine desire rather than merely physical arousal — a distinction that makes it uniquely effective for psychological or central causes of sexual dysfunction. Efficacy in both sexes distinguishes PT-141 from most sexual function treatments, which are predominantly developed for men or women. Clinical data exists for women (HSDD approval), and multiple clinical trials have demonstrated meaningful improvements in erectile function and sexual satisfaction in men, including those who have not responded to PDE5 inhibitors. Rapid onset — typically 45–60 minutes after SubQ injection — makes PT-141 a practical on-demand treatment, similar to acute PDE5 inhibitor use. Prescription accessibility via compounding pharmacies makes PT-141 among the most legally straightforward peptides to obtain through medical channels, particularly for women with an HSDD diagnosis.

Nausea is the most common and clinically significant side effect, reported in approximately 40% of patients in FDA trial data. It is typically mild to moderate, onset within 1 hour of injection, and resolves within a few hours. Taking an antiemetic (such as ondansetron) before administration is commonly recommended to manage nausea in sensitive individuals. Flushing — a sensation of warmth and redness in the face, neck, and chest — occurs in roughly 20% of users and is generally transient. Transient blood pressure elevation has been documented in clinical trials, with mean increases of approximately 6 mmHg systolic for 12 hours post-dose. This is clinically significant for individuals with pre-existing hypertension or cardiovascular conditions. Spontaneous and prolonged erections in men have been reported at higher doses — a known pharmacological effect of melanocortin agonism that is dose-dependent and manageable through dose reduction. Hyperpigmentation — transient darkening of skin, face, gums, or breasts — has been reported with repeated use, consistent with the melanocortin receptor mechanism.

FDA-approved dosing (women, HSDD): 1.75 mg administered SubQ at least 45 minutes before anticipated sexual activity. Maximum one dose per 24 hours and no more than one dose per 8 hours. Off-label dosing (men and women, research context): 1–2 mg SubQ approximately 45–60 minutes before activity. First-time users should start at 0.5–1 mg to assess nausea tolerance before increasing. Nasal spray alternative: Compounded nasal spray formulations are available from some pharmacies. Bioavailability is somewhat lower than SubQ injection, and dosing is typically 0.5–1 mg per nostril. The nasal route is preferred by users who want to avoid injections. Frequency: PT-141 is designed for as-needed use, not daily administration. Regular daily use is not established as safe or effective and increases the risk of hyperpigmentation and other side effects.

United States: PT-141 (Bremelanotide) is FDA approved under the brand name Vyleesi for HSDD in premenopausal women. It can be legally prescribed by physicians for this indication and is prepared by compounding pharmacies for off-label use. Prescription availability is the most straightforward legal pathway. WADA: PT-141 is not currently listed on the WADA prohibited substances list. Athletes in tested sports can confirm current status with their sport's governing body. Research chemical market: PT-141 is also widely available without a prescription from research chemical vendors, subject to the same quality and legal uncertainties as other research peptides.

PT-141 is primarily used as a standalone, on-demand compound rather than as part of a stacking protocol. Its acute CNS mechanism does not synergize with most other peptides in the context of a regular protocol. PT-141 + PDE5 inhibitors (sildenafil, tadalafil): This combination is occasionally used for maximum effect, with PT-141 addressing central desire and PDE5 inhibitors addressing peripheral vascular response. This combination should be used with caution given additive cardiovascular effects and should only be considered with physician oversight. PT-141 + testosterone: Men on testosterone replacement therapy who experience improved libido generally find PT-141 additive. The combination addresses hormonal drive (testosterone) and central receptor activation (PT-141).

PT-141 — Common Questions